explore -WSS

explore

author：Wikipedia 2025-09-06 02:11:24 - browse：5

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Medicare bonuses could stop drug shortages under Senate plan

WSS

FDA's Pazdur wants cancer trials to range beyond China alone

Medicare drug price lawsuits could be good politics for Biden

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Medicare bonuses could stop drug shortages under Senate plan

With trial win, GSK could get blood cancer drug back on market

What causes osteoarthritis? Researchers study link to brain protein

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

Update the Apgar Score to remove skin color

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Flu vaccine reformulation won't be easy, manufacturers warn

Dobbs anniversary: the lost opportunity of abortion as health care

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Drug repurposing or repositioning? The language matters

Future doctors need a strong humanities education

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Inaction leaves children at risk from dangerous chemotherapy drug

knowledge

Change Healthcare can notify patients about the breach, HHS says

NIH documents show early flaws of $1.6 billion long Covid program

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

What causes osteoarthritis? Researchers study link to brain protein

Update the Apgar Score to remove skin color

ASCO: Palliative care found as helpful given virtually as in person

focus

focus

hotspot

hotspot